Bosutinib for the treatment of chronic myeloid leukemia

American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Vi DoanHillary Prescott

Abstract

The pharmacology, pharmacokinetics, efficacy, and safety of the tyrosine kinase inhibitor (TKI) bosutinib in the management of chronic myeloid leukemia (CML) are reviewed. Although clinical outcomes are favorable in patients wth Philadelphia chromosome (Ph)-positive CML who receive first-line TKI therapy with imatinib, dasatinib, and nilotinib, disease progression or relapse may occur. Thus, effective second-line agents are crucial. Bosutinib (Bosulif, Pfizer Inc.) is a second-generation TKI approved for the treatment of patients with Ph-positive chronic-, accelerated-, or blast-phase CML who are intolerant or resistant to other TKIs. Bosutinib inhibits a tyrosine kinase oncogene and Src kinases responsible for CML pathogenesis. Bosutinib is primarily metabolized by cytochrome P-450 (CYP) isoenzyme 3A4; therefore, concomitant use of strong or moderate CYP3A4 inhibitors and inducers should be avoided. Bosutinib is effective in cases involving most imatinib-resistant mutations (not including the T315I and V299L mutations). Clinical trials demonstrated bosutinib's efficacy in inducing durable hematologic and cytogenetic responses, as well as high rates of progression-free and overall survival, in patients with CML who had develope...Continue Reading

References

Jul 15, 1999·The New England Journal of Medicine·S FaderlH M Kantarjian
Mar 15, 2003·The New England Journal of Medicine·Stephen G O'BrienUNKNOWN IRIS Investigators
Dec 8, 2006·The New England Journal of Medicine·Brian J DrukerUNKNOWN IRIS Investigators
Jun 8, 2010·The New England Journal of Medicine·Giuseppe SaglioUNKNOWN ENESTnd Investigators
Jun 8, 2010·The New England Journal of Medicine·Hagop KantarjianMichele Baccarani
Jun 26, 2010·International Journal of Hematology·Tadashi NagaiNoriko Usui
Sep 10, 2010·Clinical Lymphoma, Myeloma & Leukemia·Pierluigi Porcu
Dec 14, 2011·The Cancer Journal·Fabio P S SantosJorge Cortes
Sep 6, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge E CortesCarlo Gambacorti-Passerini
Oct 27, 2012·Expert Review of Anticancer Therapy·Gunhild Keller-V Amsberg, Tim H Brümmendorf
Mar 16, 2013·OncoTargets and Therapy·Gunhild Keller-von Amsberg, Steffen Koschmieder
May 16, 2013·Biologics : Targets & Therapy·Gunhild Keller-von Amsberg, Philippe Schafhausen
Nov 5, 2013·The New England Journal of Medicine·J E CortesUNKNOWN PACE Investigators
Jan 8, 2014·The Annals of Pharmacotherapy·Lindsay StansfieldTracey L Walsh-Chocolaad
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal

❮ Previous
Next ❯

Citations

Mar 25, 2016·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Yaakov CassAlexander Tabachnik
Feb 20, 2018·Molecular Cancer·Qinlian JiaoYun-Shan Wang
Oct 4, 2017·Leukemia & Lymphoma·Giuseppe Saglio, Elias Jabbour
Nov 21, 2015·American Journal of Hematology·Carlo Gambacorti-PasseriniRocco Piazza

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.